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Background
Osteoporosis is a major health problem, especially in
post-menopausal women. Current osteoporosis therapies
have major drawbacks (e.g., estrogens increase breast
cancer risks), and reduce fractures by only ~20-30%.
Most osteoporosis drugs block bone resorption, and
there is an urgent need to develop anabolic therapies that
can stimulate bone formation. We previously showed that
the NO/cGMP/PKG pathway mediates pro-proliferative
effects of mechanical stimulation in osteoblasts and
anti-apoptotic effects of estrogens in osteocytes [1,2].
These findings lead us to hypothesize that cGMP-elevating
agents may have boneprotective effects.
Results
We tested cinaciguat, a prototype soluble guanylate
cyclase stimulator, and nitrosylcobinamide (NO-Cbi), a
novel NO-donor with anti-oxidant properties, in a mouse
model of estrogen deficiency-induced osteoporosis [3].
Compared with sham-operated mice, ovariectomized
mice had lower serum cGMP concentrations, which were
largely restored to normal by treatment with cinaciguat,
NO-Cbi, or low-dose estrogen replacement. Micro-CT
analyses of tibiae showed that all three pharmacological
interventions significantly improved trabecular bone
architecture in ovariectomized animals, with similar
effect sizes. Cinaciguat and NO-Cbi reversed ovariect-
omy-induced osteocyte apoptosis as efficiently as estra-
diol, and enhanced bone formation parameters in vivo,
consistent with in vitro effects on osteoblast proliferation,
differentiation, and survival. As previously reported, ovar-
iectomy dramatically increased osteoclast numbers, and
this effect was completely reversed by estradiol. NO-Cbi
significantly decreased the number of osteoclasts in ovar-
iectomized mice, whereas cinaciguat had only modest
effects, suggesting cGMP-independent effects of NO-Cbi
in osteoclasts.
Conclusion
We conclude that estrogen deficiency represents a
state of relative NO and cGMP deficiency, and that
NO-dependent or NO-independent guanylate cyclase
stimulation may represent a novel, anabolic treatment
strategy for post-menopausal osteoporosis. These data
confirm an important role of NO/cGMP signaling in
bone biology.
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